The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2013;(2): 9‑15

Read: 1067 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2013;(2):9‑15. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220.
  2. Fonarow G.C. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med 2002;3Suppl 4:S18-S27.
  3. Yancy C.W., Lopatin M., Stevenson L.W., et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47:76-84.
  4. Shah M.R., Hasselblad V., Stinnett S.S., et al. Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. Eur J Heart Fail 2002;4:297-304.
  5. Cuffe M.S., Califf R.M., Adams K.F. Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-1547.
  6. O'Connor C.M., Gattis W.A., Adams K.F. Jr., et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003;41:1452-1457.
  7. O'Connor C.M., Gattis W.A., Teerlink J.R., et al. Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure. Am Heart J 2003;145:S47-S50.
  8. Teerlink J.R. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol 2005;96:59G-67G.
  9. Teerlink J.R. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J 2003;145:S26-S33.
  10. O'Connor C.M., Stough W.G., Gallup D.S., et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005;11:200-205.
  11. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-1540.
  12. Papp Z., Edes I., Fruhwald S., et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012;159:82-87.
  13. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-1912.
  14. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al., on behalf of the Study Investigators. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-2227.
  15. Moiseyev V.S., Poder P., Andrejevs N., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-1432.
  16. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
  17. Lilleberg J., Laine M., Palkama T., et al. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007;9:75-82.
  18. Califf R.M. Better Late Than Never. A Welcome Publication of Tardy Clinical Trial Results. J Am Coll Cardiol HF 2013;1:112-114.
  19. Brookes L. REVIVE II and SURVIVE: use of levosimendan for the treatment of acute decompensated heart failure. Medscape Education. Available at: www.medscape.org/viewarticle/523043. Accessed January 30, 2013.
  20. Lehtonen L., Sundberg S. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur J Clin Pharmacol 2002;58:449-452.
  21. Mebazaa A., Nieminen M.S., Filippatos G.S., et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009;11:304-311.
  22. Kivikko M., Antila S., Eha J., et al. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002;40:465-471.
  23. Kivikko M., Lehtonen L., Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003;107:81-86.
  24. Capomolla S., Febo O., Opasich C., et al. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 2001;3:601-610.
  25. Landoni G., Biondi-Zoccai G., Greco M., et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2012;40:634-646.
  26. O'Connor C.M., Gattis W.A., Uretsky B.F., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138:78-86.
  27. Abraham W.T., Adams K.F., Fonarow G.C., et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46:57-64.
  28. Tacon C.L., McCaffrey J., Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med 2012;38:359-367.
  29. Archan S., Toller W. Levosimendan: current status and future prospects. Curr Opin Anaesthesiol 2008;21:78-84.
  30. Lunghetti S., Palmerini E., Urselli R., et al. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure. Cardiol J 2011;18:532-537.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.